5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.
Michael Wechsler, MD, MSc
Advertisement
Michael Wechsler, MD, of National Jewish Health.
Articles by Michael Wechsler, MD, MSc
This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial
2
Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD
3
Q&A: How Lifelong Burdens Are Shaped by Childhood Eczema, With Delphine Kerob, MD
4
HCPLive Five: Pulmonology Updates at ATS 2026
5